nodes	percent_of_prediction	percent_of_DWPC	metapath
Conivaptan—Lomitapide—ABCB1—Parkinson's disease	0.0128	0.341	CrCbGaD
Conivaptan—Tolvaptan—ABCB1—Parkinson's disease	0.0114	0.304	CrCbGaD
Conivaptan—Atorvastatin—CYP2D6—Parkinson's disease	0.00778	0.208	CrCbGaD
Conivaptan—Atorvastatin—ABCB1—Parkinson's disease	0.00555	0.148	CrCbGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—EDN1—Parkinson's disease	0.00445	0.00462	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—EDN1—Parkinson's disease	0.00442	0.00459	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—HTR1A—Parkinson's disease	0.00441	0.00458	CbGpPWpGaD
Conivaptan—CYP3A4—Estrogen metabolism—NQO1—Parkinson's disease	0.00441	0.00458	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—HTR1A—Parkinson's disease	0.00438	0.00455	CbGpPWpGaD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—DRD2—Parkinson's disease	0.00435	0.00452	CbGpPWpGaD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—HTR7—Parkinson's disease	0.00435	0.00452	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—TAC1—Parkinson's disease	0.00434	0.00451	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—DRD2—Parkinson's disease	0.00432	0.00449	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—HTR7—Parkinson's disease	0.00432	0.00449	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—TAC1—Parkinson's disease	0.00431	0.00448	CbGpPWpGaD
Conivaptan—CYP3A4—Tamoxifen metabolism—CYP2D6—Parkinson's disease	0.00431	0.00447	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—GPR37—Parkinson's disease	0.00426	0.00443	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—DGKQ—Parkinson's disease	0.00426	0.00443	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—DRD1—Parkinson's disease	0.00426	0.00442	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—DGKQ—Parkinson's disease	0.00423	0.0044	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—GPR37—Parkinson's disease	0.00423	0.0044	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—DRD1—Parkinson's disease	0.00423	0.00439	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Parkinson's disease	0.00412	0.00428	CbGpPWpGaD
Conivaptan—CYP3A4—Xenobiotics—CYP2E1—Parkinson's disease	0.0041	0.00426	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—DRD3—Parkinson's disease	0.00409	0.00425	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—Parkinson's disease	0.00403	0.00419	CbGpPWpGaD
Conivaptan—AVPR1A—G alpha (q) signalling events—HTR2A—Parkinson's disease	0.00394	0.0041	CbGpPWpGaD
Conivaptan—CYP3A4—Tamoxifen metabolism—CYP2E1—Parkinson's disease	0.00394	0.00409	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PPP1R1B—Parkinson's disease	0.0039	0.00405	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PPP1R1B—Parkinson's disease	0.00387	0.00402	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—ADORA2A—Parkinson's disease	0.00387	0.00402	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—ADORA2A—Parkinson's disease	0.00384	0.00399	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—HTR7—Parkinson's disease	0.00373	0.00387	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Parkinson's disease	0.00373	0.00387	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—HTR7—Parkinson's disease	0.0037	0.00385	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—DRD2—Parkinson's disease	0.0037	0.00385	CbGpPWpGaD
Conivaptan—CYP3A4—Estrogen metabolism—COMT—Parkinson's disease	0.00369	0.00384	CbGpPWpGaD
Conivaptan—CYP3A4—Tryptophan metabolism—DDC—Parkinson's disease	0.00368	0.00382	CbGpPWpGaD
Conivaptan—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—Parkinson's disease	0.00364	0.00378	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—GRK5—Parkinson's disease	0.00356	0.00369	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—GRK5—Parkinson's disease	0.00353	0.00367	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Parkinson's disease	0.00353	0.00366	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—SLC18A2—Parkinson's disease	0.00339	0.00352	CbGpPWpGaD
Conivaptan—CYP3A4—Estrogen metabolism—GSTM1—Parkinson's disease	0.00338	0.00351	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—HTR1A—Parkinson's disease	0.00336	0.00349	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—HTR1A—Parkinson's disease	0.00333	0.00346	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—TAC1—Parkinson's disease	0.00331	0.00343	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—TAC1—Parkinson's disease	0.00328	0.00341	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—DRD1—Parkinson's disease	0.00324	0.00337	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—GRK5—Parkinson's disease	0.00323	0.00336	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—DRD1—Parkinson's disease	0.00322	0.00334	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—GRK5—Parkinson's disease	0.00321	0.00333	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—GRM4—Parkinson's disease	0.00319	0.00331	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—GRM4—Parkinson's disease	0.00317	0.00329	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—DRD3—Parkinson's disease	0.00314	0.00326	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—DRD3—Parkinson's disease	0.00312	0.00324	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—CP—Parkinson's disease	0.00312	0.00324	CbGpPWpGaD
Conivaptan—CYP3A4—Tryptophan metabolism—MAOB—Parkinson's disease	0.00309	0.00322	CbGpPWpGaD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—HTR2A—Parkinson's disease	0.00305	0.00317	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—VPS35—Parkinson's disease	0.00304	0.00316	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—HTR2A—Parkinson's disease	0.00303	0.00314	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—PENK—Parkinson's disease	0.00302	0.00314	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—VPS35—Parkinson's disease	0.00302	0.00313	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—PENK—Parkinson's disease	0.003	0.00312	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—EDN1—Parkinson's disease	0.00299	0.0031	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—EDN1—Parkinson's disease	0.00296	0.00308	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—GRM4—Parkinson's disease	0.0029	0.00301	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—GRM4—Parkinson's disease	0.00288	0.00299	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—DRD2—Parkinson's disease	0.00284	0.00295	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—HTR7—Parkinson's disease	0.00284	0.00295	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—HTR7—Parkinson's disease	0.00282	0.00293	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—DRD2—Parkinson's disease	0.00282	0.00293	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—PDYN—Parkinson's disease	0.00277	0.00287	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PENK—Parkinson's disease	0.00275	0.00285	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—PDYN—Parkinson's disease	0.00275	0.00285	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PENK—Parkinson's disease	0.00273	0.00283	CbGpPWpGaD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—Parkinson's disease	0.00268	0.00278	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Parkinson's disease	0.00261	0.00271	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Parkinson's disease	0.00259	0.00269	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—GRM5—Parkinson's disease	0.00257	0.00267	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—GRM5—Parkinson's disease	0.00255	0.00265	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—DGKQ—Parkinson's disease	0.00252	0.00262	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—GPR37—Parkinson's disease	0.00252	0.00262	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PDYN—Parkinson's disease	0.00251	0.00261	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—DGKQ—Parkinson's disease	0.0025	0.0026	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—GPR37—Parkinson's disease	0.0025	0.0026	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PDYN—Parkinson's disease	0.00249	0.00259	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—GRM5—Parkinson's disease	0.00233	0.00243	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—GRM5—Parkinson's disease	0.00232	0.00241	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PPP1R1B—Parkinson's disease	0.0023	0.00239	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PPP1R1B—Parkinson's disease	0.00229	0.00237	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—EDN1—Parkinson's disease	0.00227	0.00236	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—EDN1—Parkinson's disease	0.00226	0.00234	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—SLC6A3—Parkinson's disease	0.00222	0.00231	CbGpPWpGaD
Conivaptan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—Parkinson's disease	0.0022	0.00228	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—ADORA2A—Parkinson's disease	0.00219	0.00227	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—ADORA2A—Parkinson's disease	0.00217	0.00225	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—CYCS—Parkinson's disease	0.00213	0.00221	CbGpPWpGaD
Conivaptan—CYP3A4—Tryptophan metabolism—CYP2E1—Parkinson's disease	0.0021	0.00219	CbGpPWpGaD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—Parkinson's disease	0.00209	0.00217	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—MAOB—Parkinson's disease	0.00203	0.00211	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—RIT2—Parkinson's disease	0.00201	0.00209	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—RIT2—Parkinson's disease	0.002	0.00208	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—HTR2A—Parkinson's disease	0.00199	0.00207	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—ADORA2A—Parkinson's disease	0.00199	0.00206	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—HTR2A—Parkinson's disease	0.00197	0.00205	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—ADORA2A—Parkinson's disease	0.00197	0.00205	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—GRK5—Parkinson's disease	0.00191	0.00198	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—HTR1A—Parkinson's disease	0.0019	0.00197	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—GRK5—Parkinson's disease	0.00189	0.00197	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—HTR1A—Parkinson's disease	0.00188	0.00196	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—TAC1—Parkinson's disease	0.00187	0.00194	CbGpPWpGaD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2D6—Parkinson's disease	0.00186	0.00193	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—TAC1—Parkinson's disease	0.00185	0.00193	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	0.00185	0.00193	CbGpPWpGaD
Conivaptan—CYP3A4—Oxidation by Cytochrome P450—CYP2D6—Parkinson's disease	0.00184	0.00191	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—DRD1—Parkinson's disease	0.00183	0.0019	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—DRD1—Parkinson's disease	0.00182	0.00189	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ABCB1—Parkinson's disease	0.00178	0.00185	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—DRD3—Parkinson's disease	0.00177	0.00184	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—DRD3—Parkinson's disease	0.00176	0.00183	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—HTR1A—Parkinson's disease	0.00172	0.00179	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—GRM4—Parkinson's disease	0.00171	0.00178	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—HTR1A—Parkinson's disease	0.00171	0.00178	CbGpPWpGaD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—Parkinson's disease	0.0017	0.00177	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—GRM4—Parkinson's disease	0.0017	0.00176	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—TAC1—Parkinson's disease	0.0017	0.00176	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—TAC1—Parkinson's disease	0.00168	0.00175	CbGpPWpGaD
Conivaptan—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—Parkinson's disease	0.00168	0.00174	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—DRD1—Parkinson's disease	0.00166	0.00173	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—ADRBK1—Parkinson's disease	0.00166	0.00172	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—DRD1—Parkinson's disease	0.00165	0.00172	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—ADRBK1—Parkinson's disease	0.00164	0.00171	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PENK—Parkinson's disease	0.00162	0.00169	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MAG—Parkinson's disease	0.00162	0.00169	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—DRD3—Parkinson's disease	0.00161	0.00167	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PENK—Parkinson's disease	0.00161	0.00167	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MAG—Parkinson's disease	0.00161	0.00167	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—HTR7—Parkinson's disease	0.0016	0.00167	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—DRD2—Parkinson's disease	0.0016	0.00167	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—DRD3—Parkinson's disease	0.0016	0.00166	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—HTR7—Parkinson's disease	0.00159	0.00166	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—DRD2—Parkinson's disease	0.00159	0.00166	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2D6—Parkinson's disease	0.00151	0.00157	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—ADRBK1—Parkinson's disease	0.0015	0.00156	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—ADRBK1—Parkinson's disease	0.00149	0.00155	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PDYN—Parkinson's disease	0.00148	0.00154	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PDYN—Parkinson's disease	0.00147	0.00153	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—HTR7—Parkinson's disease	0.00146	0.00151	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—DRD2—Parkinson's disease	0.00146	0.00151	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—HTR7—Parkinson's disease	0.00145	0.0015	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—DRD2—Parkinson's disease	0.00145	0.0015	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—GFAP—Parkinson's disease	0.00139	0.00145	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—GFAP—Parkinson's disease	0.00138	0.00144	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—GRM5—Parkinson's disease	0.00138	0.00143	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—Parkinson's disease	0.00138	0.00143	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—GRM5—Parkinson's disease	0.00137	0.00142	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—EDN1—Parkinson's disease	0.00128	0.00133	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—EDN1—Parkinson's disease	0.00128	0.00133	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	0.00122	0.00127	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—FGF20—Parkinson's disease	0.00121	0.00126	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTA4—Parkinson's disease	0.00121	0.00126	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—FGF20—Parkinson's disease	0.0012	0.00125	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—GSTA4—Parkinson's disease	0.00119	0.00124	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ADORA2A—Parkinson's disease	0.00117	0.00122	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—EDN1—Parkinson's disease	0.00117	0.00121	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ADORA2A—Parkinson's disease	0.00116	0.00121	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—EDN1—Parkinson's disease	0.00116	0.0012	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—Parkinson's disease	0.00113	0.00118	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—HTR2A—Parkinson's disease	0.00112	0.00117	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—HTR2A—Parkinson's disease	0.00112	0.00116	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—INSR—Parkinson's disease	0.00108	0.00112	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—MAOB—Parkinson's disease	0.00108	0.00112	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—INSR—Parkinson's disease	0.00107	0.00112	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—FGB—Parkinson's disease	0.00102	0.00106	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—HTR2A—Parkinson's disease	0.00102	0.00106	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—HTR1A—Parkinson's disease	0.00102	0.00106	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—FGB—Parkinson's disease	0.00102	0.00106	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—HTR2A—Parkinson's disease	0.00101	0.00105	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—HTR1A—Parkinson's disease	0.00101	0.00105	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TAC1—Parkinson's disease	0.001	0.00104	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TAC1—Parkinson's disease	0.000995	0.00103	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—DRD1—Parkinson's disease	0.000983	0.00102	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—DRD1—Parkinson's disease	0.000976	0.00101	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—DRD3—Parkinson's disease	0.000952	0.000989	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—DRD3—Parkinson's disease	0.000945	0.000982	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ADRBK1—Parkinson's disease	0.000889	0.000923	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ADRBK1—Parkinson's disease	0.000882	0.000917	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—HTR7—Parkinson's disease	0.000861	0.000894	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—DRD2—Parkinson's disease	0.000861	0.000894	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—HTR7—Parkinson's disease	0.000855	0.000888	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—DRD2—Parkinson's disease	0.000855	0.000888	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—CYP2D6—Parkinson's disease	0.000801	0.000832	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP2D6—Parkinson's disease	0.00079	0.000821	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—CYP2E1—Parkinson's disease	0.000732	0.000761	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP2E1—Parkinson's disease	0.000722	0.00075	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IGF2—Parkinson's disease	0.000721	0.000749	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IGF2—Parkinson's disease	0.000716	0.000744	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IGF1R—Parkinson's disease	0.000697	0.000725	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IGF1R—Parkinson's disease	0.000692	0.000719	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—EDN1—Parkinson's disease	0.000689	0.000716	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—EDN1—Parkinson's disease	0.000684	0.000711	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—NGF—Parkinson's disease	0.000633	0.000658	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—NGF—Parkinson's disease	0.000629	0.000653	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—COMT—Parkinson's disease	0.000607	0.00063	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTP1—Parkinson's disease	0.000604	0.000628	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—HTR2A—Parkinson's disease	0.000603	0.000626	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—MAOA—Parkinson's disease	0.000603	0.000626	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—COMT—Parkinson's disease	0.000599	0.000622	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—HTR2A—Parkinson's disease	0.000599	0.000622	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—GSTP1—Parkinson's disease	0.000596	0.000619	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—APOE—Parkinson's disease	0.00056	0.000582	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—APOE—Parkinson's disease	0.000556	0.000578	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTM1—Parkinson's disease	0.000555	0.000577	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—GSTM1—Parkinson's disease	0.000547	0.000569	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—INS—Parkinson's disease	0.000479	0.000497	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—INS—Parkinson's disease	0.000475	0.000494	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ND3—Parkinson's disease	0.000394	0.000409	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—MCCC1—Parkinson's disease	0.000394	0.000409	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—OMD—Parkinson's disease	0.00037	0.000384	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—TALDO1—Parkinson's disease	0.00037	0.000384	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CASP3—Parkinson's disease	0.000356	0.00037	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—IL6—Parkinson's disease	0.000354	0.000368	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CASP3—Parkinson's disease	0.000354	0.000368	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—IL6—Parkinson's disease	0.000352	0.000365	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—NDUFB11—Parkinson's disease	0.000351	0.000364	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GCH1—Parkinson's disease	0.000335	0.000348	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MAPK8—Parkinson's disease	0.000328	0.00034	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MAPK8—Parkinson's disease	0.000325	0.000338	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—FBP1—Parkinson's disease	0.000298	0.00031	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—DBH—Parkinson's disease	0.000298	0.00031	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GBA—Parkinson's disease	0.000298	0.00031	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—DDC—Parkinson's disease	0.000219	0.000227	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IL6—Parkinson's disease	0.000209	0.000217	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IL6—Parkinson's disease	0.000208	0.000216	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTA4—Parkinson's disease	0.000207	0.000215	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	0.000186	0.000193	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—MAOB—Parkinson's disease	0.000184	0.000191	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	0.000137	0.000142	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CTGF—Parkinson's disease	0.000134	0.00014	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	0.000125	0.00013	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—NQO1—Parkinson's disease	0.000124	0.000129	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—TH—Parkinson's disease	0.000122	0.000127	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYCS—Parkinson's disease	0.000117	0.000122	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—COMT—Parkinson's disease	0.000104	0.000108	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTP1—Parkinson's disease	0.000103	0.000107	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—MAOA—Parkinson's disease	0.000103	0.000107	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—HMOX1—Parkinson's disease	0.000102	0.000106	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ABCB1—Parkinson's disease	9.78e-05	0.000102	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTM1—Parkinson's disease	9.49e-05	9.86e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GPX1—Parkinson's disease	9.09e-05	9.44e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—MTHFR—Parkinson's disease	8.39e-05	8.72e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—APOE—Parkinson's disease	7.81e-05	8.11e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—INS—Parkinson's disease	6.67e-05	6.93e-05	CbGpPWpGaD
